Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

11.54 +0.18 (+1.58%)

Streaming Delayed Price Updated: 1:11 PM EDT, Sep 3, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,764,977
Open	11.58
Bid (Size)	11.53 (1,000)
Ask (Size)	11.55 (1,000)
Prev. Close	11.36
Today's Range	11.26 - 11.82
52wk Range	2.745 - 12.58
Shares Outstanding	287,686,199
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026

September 02, 2026

From AbCellera Biologics Inc.

Via Business Wire

Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.

August 19, 2026

News Provided by USA News Group on behalf of MindWalk Holdings Corp.

From USA News Group

Via GlobeNewswire

Performance

YTD	+236.4%	+236.4%
1 Month	+97.9%	+97.9%
3 Month	+101.7%	+101.7%
6 Month	+217.9%	+217.9%
1 Year	+184.9%	+184.9%

More News

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

August 13, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Biologics (NASDAQ:ABCL) Misses Q2 Estimates, Falls Short on Revenue and EPS ↗

August 05, 2026

Via Chartmill

AbCellera (ABCL) Q2 2026 Earnings Call Transcript ↗

August 12, 2026

Via The Motley Fool

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

August 11, 2026

From AbCellera Biologics Inc.

Via Business Wire

Here are the top movers in Monday's session. ↗

August 10, 2026

Via Chartmill

There are notable gap-ups and gap-downs in today's session. ↗

August 10, 2026

Via Chartmill

AI Found an Influenza Target That Survives Viral Mutation

August 10, 2026

From Equity Insider

Via GlobeNewswire

AbCellera’s ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial ↗

August 10, 2026

Via MarketBeat

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

August 10, 2026

From AbCellera Biologics Inc.

Via Business Wire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

August 07, 2026

Via Benzinga

Get insights into the top gainers and losers of Friday's after-hours session. ↗

August 07, 2026

Via Chartmill

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

August 07, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Biologics Q2 Earnings Call Highlights ↗

August 05, 2026

Via MarketBeat

AbCellera Reports Q2 2026 Business Results

August 05, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

July 29, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026

July 07, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Appoints Dr. Lynn Seely to its Board of Directors

July 06, 2026

From AbCellera Biologics Inc.

Via Business Wire

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

June 17, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Appoints Dr. Victor Sandor to its Board of Directors

June 05, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Biologics Bets on Hot Flash Antibody as Pipeline Pivot Gains Steam ↗

June 04, 2026

Via MarketBeat

AbCellera Biologics Q1 Earnings Call Highlights ↗

May 11, 2026

Via MarketBeat

AbCellera (ABCL) Q1 2026 Earnings Transcript ↗

May 11, 2026

Via The Motley Fool

Stay updated with the stocks that are on the move in today's after-hours session. ↗

May 11, 2026

Via Chartmill

Frequently Asked Questions

Is AbCellera Biologics Inc. - Common Shares publicly traded?

Yes, AbCellera Biologics Inc. - Common Shares is publicly traded.

What exchange does AbCellera Biologics Inc. - Common Shares trade on?

AbCellera Biologics Inc. - Common Shares trades on the Nasdaq Stock Market

What is the ticker symbol for AbCellera Biologics Inc. - Common Shares?

The ticker symbol for AbCellera Biologics Inc. - Common Shares is ABCL on the Nasdaq Stock Market

What is the current price of AbCellera Biologics Inc. - Common Shares?

The current price of AbCellera Biologics Inc. - Common Shares is 11.54

When was AbCellera Biologics Inc. - Common Shares last traded?

The last trade of AbCellera Biologics Inc. - Common Shares was at 09/03/26 01:11 PM ET

What is the market capitalization of AbCellera Biologics Inc. - Common Shares?

The market capitalization of AbCellera Biologics Inc. - Common Shares is 3.32B

How many shares of AbCellera Biologics Inc. - Common Shares are outstanding?

AbCellera Biologics Inc. - Common Shares has 3B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.